^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CDK1 overexpression

i
Other names: CDK1, CDC2, CDC28A, Cyclin-dependent kinase 1
Entrez ID:
15d
Caffeic acid phenethyl ester suppresses the expression of androgen receptor variant 7 via inhibition of CDK1 and AKT. (PubMed, Cancer Gene Ther)
Intraperitoneal injection of 10 mg/kg CAPE retarded the growth of 22Rv1 xenografts in nude mice and suppressed the protein levels of AR-V7, CDK1 and AKT in 22Rv1 xenografts. Our study provided the rationale of applying CAPE for inhibition of AR-V7 in prostate tumors.
Journal
|
AR (Androgen receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDK1 (Cyclin-dependent kinase 1)
|
AR overexpression • AR expression • AR splice variant 7 • AR-V7 expression • AKT1 overexpression • AR-V7 overexpression • AR splice variant 7 expression • CDK1 overexpression
4ms
HADHA promotes ovarian cancer outgrowth via up-regulating CDK1. (PubMed, Cancer Cell Int)
Our study highlights the involvement of HADHA in ovarian cancer tumorigenesis and suggests its potential as a promising prognostic marker in ovarian cancer. Through its regulation of CDK1, HADHA influences critical cellular processes in ovarian cancer, providing insights into its pathogenic mechanism.
Journal
|
CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression
6ms
Post-translational modification of CDK1-STAT3 signaling by fisetin suppresses pancreatic cancer stem cell properties. (PubMed, Cell Biosci)
Our findings highlight the role of post-translational modifications of CDK1-STAT3 signaling in maintaining cancer stemness of PDAC, and indicated that targeting the CDK1-STAT3 axis with inhibitors such as fisetin is a potential therapeutic strategy to diminish drug resistance and eliminate PDAC.
Journal • Cancer stem
|
CDK1 (Cyclin-dependent kinase 1) • HDAC3 (Histone Deacetylase 3)
|
STAT3 expression • CDK1 overexpression
|
gemcitabine
7ms
Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis. (PubMed, J Exp Clin Cancer Res)
Our study highlights that YOD1 functions as an oncogene in TNBC via binding to CDK1 and mediated its stability and oncogenic activity. Interfering with YOD1 expression or YOD1 inhibitor could suppress TNBC cells in vitro and in vivo, suggesting that YOD1 may prove to be a promising therapeutic target for TNBC.
Journal
|
CDK1 (Cyclin-dependent kinase 1) • YOD1 (YOD1 Deubiquitinase)
|
CDK1 overexpression
|
cisplatin • paclitaxel
7ms
KNTC1 knockdown inhibits proliferation and metastases of liver cancer. (PubMed, 3 Biotech)
Inhibition of high expression of KNTC1 in hepatocellular carcinoma was effective in suppressing the progression of hepatocellular carcinoma cells after knockdown. It may be a potential target for the treatment of hepatocellular carcinoma.
Journal
|
CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression
8ms
Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer. (PubMed, Int J Mol Sci)
The treatment of KpB mice with RO-3306 for four weeks showed a significant decrease in tumor weight under obese and lean conditions without obvious side effects. Overall, our results demonstrate that the inhibition of CDK1 activity by RO-3306 effectively reduces cell proliferation and tumor growth, providing biological evidence for future clinical trials of CDK1 inhibitors in ovarian cancer.
Preclinical • Journal
|
CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression
8ms
Rucaparib inhibits lung adenocarcinoma cell proliferation and migration via the SHCBP1/CDK1 pathway. (PubMed, FEBS J)
In addition, we proposed that rucaparib may be a small-molecule inhibitor of SHCBP1 and validated both in vitro and in vivo that rucaparib inhibits cell proliferation and migration via suppression of the SHCBP1/CDK1 pathway in LUAD. Our study elucidates a newly identified role of SHCBP1 in promoting cell proliferation and migration in LUAD, and suggests rucaparib as a potential inhibitor for LUAD treatment.
Journal • PARP Biomarker
|
CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression
|
Rubraca (rucaparib)
9ms
Curcumin targets miR-134-5p to suppress the progression of colorectal cancer through regulating the CDCA3/CDK1 pathway. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
In addition, curcumin treatment repressed tumor growth in colorectal cancer via increasing miR-134-5p and downregulating CDCA3 and CDK1 expression in vivo. Our findings provided the evidence that curcumin upregulated miR-134-5p to inhibit the progression of colorectal cancer by regulating CDCA3/CDK1 pathway.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CDCA3 (Cell Division Cycle Associated 3) • MMP9 (Matrix metallopeptidase 9) • CDK1 (Cyclin-dependent kinase 1)
|
CDCA3 overexpression • CDK1 overexpression
12ms
Identification of prognosis-related cyclin-dependent kinases and potential response drugs in hepatocellular carcinoma. (PubMed, J Cancer Res Ther)
CDK1 and CDK4 may be potential prognostic biomarkers for HCC. Moreover, targeting four transcription factors (E2F1, PTTG1, RELA, and SP1) combined with immunotherapy may be a new therapeutic strategy for treating HCC patients with high CDK1 and CDK4 expression, especially hepatitis-related HCC.
Journal • IO biomarker
|
PGR (Progesterone receptor) • CDK4 (Cyclin-dependent kinase 4) • CD4 (CD4 Molecule) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • CDK1 (Cyclin-dependent kinase 1) • E2F1 (E2F transcription factor 1) • RELA (RELA Proto-Oncogene)
|
PGR expression • CDK1 overexpression
1year
Prognostic and immunological characteristics of CDK1 in lung adenocarcinoma: A systematic analysis. (PubMed, Front Oncol)
CDK1 was an independent prognostic factor for LUAD and improved the ability to predict overall survival when combined with tumor stage. CDK1 plays an essential role in reshaping the tumor immune microenvironment and might be a prognostic and treatment biomarker in LUAD.
Journal • IO biomarker
|
SPP1 (Secreted Phosphoprotein 1) • CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression
1year
Identification of NLE1/CDK1 axis as key regulator in the development and progression of non-small cell lung cancer. (PubMed, Front Oncol)
Both CDK1 overexpression and treatment of Akt pathway activator could reverse the NLE1 knockdown induced NSCLC inhibition to some extent. In conclusion, this study identified NLE1 as a novel tumor promotor in the development and progression of NSCLC, which may be a potential therapeutic target in the treatment of NSCLC.
Journal
|
CDK1 (Cyclin-dependent kinase 1) • E2F1 (E2F transcription factor 1)
|
CDK1 overexpression
1year
Compound K is a potential clinical anticancer agent in prostate cancer by arresting cell cycle. (PubMed, Phytomedicine)
CK can inhibit PCa cells, and the mechanisms may be associated with the inhibition of cell cycle pathways through CDK1. CK is also a potential clinical anticancer agent for treating PCa.
Journal
|
CCNA2 (Cyclin A2) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1)
|
CDK1 overexpression
|
docetaxel
over1year
ASRGL1 downregulation suppresses hepatocellular carcinoma tumorigenesis in a CDK1-dependent manner. (PubMed, Dig Liver Dis)
Moreover, CDK1 overexpression was able to reverse the decreased proliferation, migration and invasion of HepG2 cells induced by ASRGL1 knockdown. Collectively, our studies indicate that ASRGL1 blockade functions to inhibit cyclin B/CDK1-dependent cell cycle, leading to G2-to-M phase transition failure and tumor suppression in HCC.
Journal
|
CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression
over1year
Identification of novel piperazine-tethered phthalazines as selective CDK1 inhibitors endowed with in vitro anticancer activity toward the pancreatic cancer. (PubMed, Eur J Med Chem)
Western blotting of CDK1 in MDA-PATC53 cells confirmed the ability of target phthalazines to diminish the CDK1 levels, and cell cycle analyses revealed their ability to arrest the cell cycle at G2/M phase. In conclusion, a panel of potent and selective CDK1 inhibitors were identified which can serve as lead compounds for designing further CDK1 inhibitors.
Preclinical • Journal
|
BRAF (B-raf proto-oncogene) • FGFR (Fibroblast Growth Factor Receptor) • AXL (AXL Receptor Tyrosine Kinase) • JAK1 (Janus Kinase 1) • CDK1 (Cyclin-dependent kinase 1) • PTK2B (Protein Tyrosine Kinase 2 Beta)
|
CDK1 overexpression
|
dinaciclib (MK-7965)
over1year
Identification and validation of real hub genes in hepatocellular carcinoma based on weighted gene co-expression network analysis. (PubMed, Cancer Biomark)
High expression of these three genes was negatively correlated with survival time in HCC, and the expression of CDK1, CCNA2, and CDC20 were significantly higher in tumor tissues of HCC patients than in normal liver tissues as verified again by the HPA database. All in all, this provides a new feasible target for early and accurate diagnosis of HCC, clinical diagnosis, treatment, and prognosis.
Journal
|
CCNA2 (Cyclin A2) • CDC20 (Cell Division Cycle 20) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • CEP55 (Centrosomal Protein 55) • KIF20A (Kinesin Family Member 20A)
|
CDK1 overexpression
over1year
CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis. (PubMed, J Transl Med)
CDK1 could be exploited as an essential therapeutic target of ACC via regulating the EMT, the G2/M checkpoint, and PANoptosis. Thus, CurE may be a potential candidate drug for ACC therapy with good safety and efficacy, which will meet the great need of patients with ACC.
Journal
|
AURKA (Aurora kinase A) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • CDK1 (Cyclin-dependent kinase 1) • SNAI2 (Snail Family Transcriptional Repressor 2) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
|
CDK1 overexpression
|
Lysodren (mitotane)
over1year
The CDK1-Related lncRNA and CXCL8 Mediated Immune Resistance in Lung Adenocarcinoma. (PubMed, Cells)
This study explained that LINC00261, CDK1, and CXCL8 may have a mutual regulation relationship, which affects the occurrence of LUAD and the efficacy of immunotherapy.
Journal • IO biomarker
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression • CXCL8 overexpression
over1year
Expression of KIF2A, NDC80, CDK1, and CCNB1 in breast cancer patients: Their interaction and linkage with tumor features and prognosis. (PubMed, J Clin Lab Anal)
KIF2A correlates with NDC80, CDK1, CCNB1, and may link with advanced tumor stages and poor prognosis in breast cancer patients.
Journal
|
CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
|
CDK1 overexpression
over1year
Exploration and validation of metastasis-associated genes for skin cutaneous melanoma. (PubMed, Sci Rep)
In addition, we identified that CDK1 had a close interaction with 10 antitumor drugs. CDK1 was identified as a hub gene involved in the progression of melanoma metastasis and may be regarded as a therapeutic target for melanoma patients to improve prognosis and prevent metastasis in the future.
Journal
|
FOXM1 (Forkhead Box M1) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • RFC4 (Replication Factor C Subunit 4)
|
CDK1 overexpression
over1year
ZEB1 induces N-cadherin expression in human glioblastoma and may alter patient survival. (PubMed, Mol Clin Oncol)
A linear correlation between ZEB1 and CDH2 and CDK1 expression was observed in GBM. Moreover, ZEB1 was involved in EMT (e.g., signaling in human GBM) and high ZEB1 levels were linked to an aberrant cell cycle processing, marked by CDK1 overexpression.
Journal
|
CDH1 (Cadherin 1) • CDH2 (Cadherin 2) • CDK1 (Cyclin-dependent kinase 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
CDH1 expression • CDK1 overexpression • ZEB1 expression
over1year
Arecoline promotes proliferation and migration of human HepG2 cells through activation of the PI3K/AKT/mTOR pathway. (PubMed, Hereditas)
A low concentration arecoline can induce the proliferation and migration of HepG2 cells, with the potential mechanism of action linked to high levels of exosomal miR-21 and miR-1267, activation of the PI3K-AKT pathway, upregulation of CDK1 and CCND1, and downregulation of RAF1.
Journal
|
CCND1 (Cyclin D1) • MIR21 (MicroRNA 21) • CDK1 (Cyclin-dependent kinase 1) • CDKN1B (Cyclin dependent kinase inhibitor 1B)
|
CCND1 expression • CDK1 overexpression
over1year
The CDK1/TFCP2L1/ID2 cascade offers a novel combination therapy strategy in a preclinical model of bladder cancer. (PubMed, Exp Mol Med)
Combination treatment with the specific CDK1 inhibitor RO-3306 and apigenin significantly suppressed tumor growth in an orthotopic BC xenograft animal model. This study demonstrates the biological role and clinical utility of ID2 as a direct target of the CDK1-TFCP2L1 pathway for modulating the stemness features of BC cells.
Preclinical • Journal • Combination therapy
|
ID2 (Inhibitor Of DNA Binding 2) • CDK1 (Cyclin-dependent kinase 1) • TFCP2 (Transcription Factor CP2)
|
CDK1 overexpression
over1year
Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors. (PubMed, Med Oncol)
Additionally, dinaciclib analogs are prospective replacements for dinaciclib since they exhibit increased binding affinity, consistent with MDS findings, and have acceptable ADMET qualities. The discovery of new compounds may pave the road for their future application in cancer prevention through basic, preclinical, and clinical research.
Journal
|
CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression
|
dinaciclib (MK-7965)
almost2years
Expression pattern and prognostic significance of CDKs in breast cancer: An integrated bioinformatic study. (PubMed, Cancer Biomark)
The study's multimodal analytical methodologies imply that modulating CDKs for BC treatment is a promising approach.
Journal
|
CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression
almost2years
CDCA8 Contributes to the Development and Progression of Thyroid Cancer through Regulating CDK1. (PubMed, J Cancer)
CDCA8 functions as an oncogene in thyroid cancer, and CDCA8 knockdown suppresses cancer development in vitro and in vivo. Additionally, CDK1 was further identified as a potential target of CDCA8 in thyroid cancer.
Journal
|
CDK1 (Cyclin-dependent kinase 1) • CDCA8 (Cell Division Cycle Associated 8)
|
CDK1 overexpression
almost2years
IncRNA KTN1-AS1 Silencing Inhibits Non-Small-Cell Lung Cancer Cell Proliferation and KTN1-AS1 Expression Predicts Survival. (PubMed, Crit Rev Eukaryot Gene Expr)
Moreover, KTN1-AS1 silencing suppressed NSCLC cell proliferation and CDK1 overexpression attenuated the effects of KTN1-AS1 silencing on cell proliferation. KTN1-AS1 may regulate cell cycle progression in NSCLC by regulating CDK1.
Journal
|
CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression
almost2years
Suppression of CCT3 inhibits melanoma cell proliferation by downregulating CDK1 expression. (PubMed, J Cancer)
Additionally, Functional rescues experiments also indicated that decreased cell proliferation due to CCT3 silencing was rescued by CDK1 overexpression. Overall, our findings suggest that CCT3 depletions prohibited melanoma progression by downregulating CDK1 expression and is a potential therapeutic target for melanoma.
Journal
|
CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression
almost2years
Screening of differentially expressed genes for colorectal cancer and prediction of potential traditional Chinese medicine: based on bioinformatics (PubMed, Zhongguo Zhong Yao Za Zhi)
Thus, the two can be used as biomarkers for the diagnosis and treatment of CRC. This study provides a reference for related drug development.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • TOP2A (DNA topoisomerase 2-alpha) • AURKA (Aurora kinase A) • MELK (Maternal Embryonic Leucine Zipper Kinase) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • CDC20 (Cell Division Cycle 20) • CDK1 (Cyclin-dependent kinase 1) • TRIP13 (Thyroid Hormone Receptor Interactor 13) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • CEP55 (Centrosomal Protein 55)
|
KRAS mutation • CDK1 overexpression
almost2years
NCAPD2 promotes breast cancer progression through E2F1 transcriptional regulation of CDK1. (PubMed, Cancer Sci)
Overexpression of CDK1 alleviated the inhibitory effects of NCAPD2 knockdown in BC cells. In summary, NCAPD2/ E2F1/CDK1 axis may play a role in promoting the progression of BC, which may provide a blueprint for molecular therapy.
Journal
|
CDK1 (Cyclin-dependent kinase 1) • E2F1 (E2F transcription factor 1)
|
CDK1 overexpression
2years
Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma. (PubMed, BMC Gastroenterol)
HCC patients with high CDK4 expression have poor prognosis, and CDK4 could be a potential candidate diagnostic biomarker for HCC.
Journal
|
CDK4 (Cyclin-dependent kinase 4) • CDK1 (Cyclin-dependent kinase 1)
|
CDK4 overexpression • CDK1 overexpression
over2years
CircCDK1 knockdown reduces CDK1 expression by targeting miR-489-3p to suppress the development of breast cancer and strengthen the sensitivity of Tamoxifen. (PubMed, Anticancer Drugs)
CircCDK1 knockdown was verified to enhance Tamoxifen sensitivity in animal models. CircCDK1 knockdown enhanced the sensitivity of Tamoxifen in breast cancer cells and suppressed cell growth and survival by depleting CDK1 expression via releasing miR- 489-3p.
Journal
|
CASP3 (Caspase 3) • CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression
|
tamoxifen
over2years
MicroRNA-195-3p inhibits cyclin dependent kinase 1 to induce radiosensitivity in nasopharyngeal carcinoma. (PubMed, Bioengineered)
CDK1 was a target gene of miR-195-3p, and CDK1 overexpression counteracted the effects of miR-195-3p on NPC cell growth, apoptosis, cell cycle progression and radiosensitivity. In summary, miR-195-3p improves the radiosensitivity of NPC cells by targeting and regulating CDK1.
Journal
|
CDK1 (Cyclin-dependent kinase 1) • MIR195 (MicroRNA 195)
|
CDK1 overexpression
over2years
Overexpression of cyclin-dependent kinase 1 in esophageal squamous cell carcinoma and its clinical significance. (PubMed, FEBS Open Bio)
A triple regulatory network of PVT1-hsa-miR-145-5p/hsa-miR-30c-5p-CDK1 was constructed using in silico analysis. In summary, overexpression of CDK1 is closely related to ESCC tumorigenesis.
Clinical • Journal
|
CDK1 (Cyclin-dependent kinase 1) • PVT1 (Pvt1 Oncogene) • MIR30C
|
CDK6 overexpression • CDK1 overexpression
over2years
Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). (PubMed, Cancers (Basel))
To conclude, CDK1 inhibition induces G2/M cell cycle arrest, stimulates apoptosis, and specifically targets CSCs, which makes it a promising treatment for PDAC. Screening of patients for CDK1 overexpression and further research into combination treatments is essential for optimizing this novel targeted therapy.
Review • Journal
|
CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression
over2years
Effect of CDK1 Interferes with the Regulation of PLK1, Aurora B and TRF1 on the Proliferation of Leukemia Cells (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Knocking out CDK1 can inhibit the phosphorylation of PLK1 and Aurora B and negatively regulate TRF1, thereby inhibiting the proliferation of leukemia cells.
Journal
|
PLK1 (Polo Like Kinase 1) • CCNA2 (Cyclin A2) • CDK1 (Cyclin-dependent kinase 1) • TERF1 (Telomeric Repeat Binding Factor 1)
|
CDK1 overexpression • CDKN1B expression
over2years
MiR-495-3p and miR-143-3p co-target CDK1 to inhibit the development of cervical cancer. (PubMed, Clin Transl Oncol)
Taken together, miR-143-3p and miR-495-3p co-target CDK1, thereby inhibiting the occurrence and development of cervical cancer.
Journal
|
CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression
almost3years
PARP and CDK4/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer. (PubMed, Mol Cancer Ther)
We analyzed the efficacy and mechanistic interactions of PARP inhibition (PARPi) (olaparib) and CDK4/6 inhibition (CDK4/6i) (palbociclib or abemaciclib) combination therapy in castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) models. Our study defines a novel combination treatment strategy for CRPC and NEPC and demonstrates that combination PARPi and CDK4/6i synergistically promotes suppression of the p-Rb1-E2F1 axis and E2F1 target genes, including CDK1 and NED proteins, leading to growth inhibition and increased apoptosis in vitro and in vivo. Taken together, our results provide a molecular rationale for PARPi and CDK4/6i combination therapy and reveal mechanism-based clinical trial opportunities for men with NEPC.
Journal • Combination therapy • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • RB1 (RB Transcriptional Corepressor 1) • CDK1 (Cyclin-dependent kinase 1) • E2F1 (E2F transcription factor 1)
|
CDK1 overexpression
|
Lynparza (olaparib) • Ibrance (palbociclib) • Verzenio (abemaciclib)
almost3years
DNMT3A Mutation-Induced CDK1 Overexpression Promotes Leukemogenesis by Modulating the Interaction between EZH2 and DNMT3A. (PubMed, Biomolecules)
CDK1 selective inhibitor CGP74514A (CGP) and the pan-CDK inhibitor flavopiridol (FLA) arrested OCI-AML3 cells in the G2/M phase, and induced cell apoptosis...Moreover, the combined application of CDK1 inhibitor and traditional chemotherapy drugs synergistically inhibited proliferation and induced apoptosis of OCI-AML3 cells. In conclusion, this study highlights CDK1 overexpression as a pathogenic factor and a potential therapeutic target for DNMT3A mutation-related AML.
Journal
|
DNMT3A (DNA methyltransferase 1) • CD163 (CD163 Molecule) • CDK1 (Cyclin-dependent kinase 1)
|
DNMT3A mutation • DNMT3A R882H • CDK1 overexpression • DNMT3A R882
|
alvocidib (DSP-2033)
almost3years
DPP3/CDK1 contributes to the progression of colorectal cancer through regulating cell proliferation, cell apoptosis, and cell migration. (PubMed, Cell Death Dis)
Overexpression of CDK1 alleviates the inhibitory effects of DPP3 knockdown in CRC cells. In summary, DPP3 has oncogene-like functions in the development and progression of CRC by targeting CDK1, which may be an effective molecular target for the prognosis and treatment of CRC.
Journal
|
CASP3 (Caspase 3) • CASP8 (Caspase 8) • CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • DPP3 (Dipeptidyl Peptidase 3)
|
CDK1 overexpression • CDKN1B expression
almost3years
miR-378a-5p inhibits the proliferation of colorectal cancer cells by downregulating CDK1. (PubMed, World J Surg Oncol)
The results of this study help to elucidate the mechanism by which miR-378a-5p can be used as a tumor marker to inhibit the growth of colorectal cancer and CDK1, which is related to the prognosis of colorectal cancer patients. MiR-378a-5p inhibits CRC cell proliferation by suppressing CDK1 expression, which may become a possible therapeutic target for treatment of CRC.
Journal
|
CDK1 (Cyclin-dependent kinase 1)
|
CDK1 overexpression